Results
vitreous hemorrhage, TRD, NVG, fifty-four
VITREOUS HEMORRHAGE, NEOVASCULAR GLAUCOMA, ENDOPHTHALMITIS, VITREOUS HEMORRHAGE, RESOLUTION
One hundred fifty-four eyes were enrolled in the study and allocated randomly into two groups: 78 eyes in the IVA group and 76 eyes in the control group. During follow-up, 26 eyes were excluded: 16 cases because of the loss of follow-up and 10 eyes because of the administration of intravitreal silicone oil injection. For the final data analysis, 64 eyes in each group were included.Patient demographics and preoperative clinical findings of the two groups are summarized in Patient demographics and preoperative clinical findings of the two groups.The VH incidences in the IVA group and the control group were 14.8 and 39.3% at week 1, 8.6 and 31.7% at month 1, 11.7 and 30.5% at month 2, and 8.6 and 30.5% at month 3, respectively. Intergroup differences showed a significantly decreased VH rate in the IVA group compared with that of the control group at week 1, month 1, and month 3 (Vitreous hemorrhage grading in the two groups. The number of patients with different categories of vitreous hemorrhage grading in the preoperative intravitreal aflibercept (IVA) injection group and control group (bar with dotted pattern) during follow-up.The mean BCVA changes in the logMAR scale were better in the IVA group than in the control group at week 1, month 1, month 2, and month 3 after surgery (0.70 vs. 0.81, 0.50 vs. 0.67, 0.51 vs. 0.66, and 0.46 vs. 0.65, respectively), but the difference between the two groups was not statistically significant at each visit point (The mean best-corrected visual acuity (BCVA) at each visit in the two groups. The mean BCVA in logMAR (Logarithm of the Minimum Angle of Resolution) scale at baseline, week 1, month 1, month 2, and month 3 after surgery in the preoperative intravitreal aflibercept (IVA) injection group and control group.The mean best-corrected visual acuity (BCVA) change comparing to baseline during follow-up in the two groups. The mean BCVA change in logMAR (Logarithm of the Minimum Angle of Resolution) scale at week 1, month 1, month 2, and month 3 after surgery comparing to baseline in the preoperative intravitreal aflibercept (IVA) injection group and control group.The number of patients with different categories of best-corrected visual acuity (BCVA) improvement in the two groups. The number of patients with different categories of BCVA improvement in logMAR (Logarithm of the Minimum Angle of Resolution) scale at week 1, month 1, month 2, and month 3 after surgery comparing to baseline in the preoperative intravitreal aflibercept (IVA) injection group and control group (bar with dotted pattern).There were no incidences of neovascular glaucoma (NVG), endophthalmitis, or TRD progression in the cases included for the final analysis.